https://www.selleckchem.com/products/ly333531.html
834, 0.397-1.753). In small, higher-risk subgroup (n = 17); however, 2-year landmark DFS in ≥ 3-year group was significantly longer (HR 0.095, 0.011-0.85 than that in 2-year group. The incidence of bone-related adverse events was around 5% in both groups. Adjuvant leuprorelin treatment for ≥ 3years with tamoxifen only showed similar efficacy and safety profiles to those for 2years in analyses among all patients but suggested greater benefit in higher-risk patients. No new safety signal was identified for long-term leuprorelin treatme